Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZG-2686
- Development stage
- Unknown
- Lead developer
- China Pharmaceutical University
01
Overview
ZG-2686: sourced facts only. name: "Here, we identify compound 48 (ZG-2686), a 3-(benzamido)pyrazolopyridine derivative, as a novel and potent HIF-2α agonist (Emax = 375.7 ± 9.7%, EC50 = 0.25 ± 0.05 μM)." [PMID:41267442]; target: "Here, we identify compound 48 (ZG-2686), a 3-(benzamido)pyrazolopyridine derivative, as a novel and potent HIF-2α agonist (Emax = 375.7 ± 9.7%, EC50 = 0.25 ± 0.05 μM)." [PMID:41267442]; developer: "State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 211198, China." [PMID:41267442]
02
Targets
EPAS1 (Hypoxia-inducible factor 2-alpha)
Beyond the preview
Go deeper on ZG-2686.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZG-2686.